Prescription Drug Cost Management Resources
As the 2017 state legislative sessions kick off, NASHP is continuing our work tracking legislative action on pharmaceutical pricing. Last year, states introduced dozens of bills on pharmaceutical prices, and the trend is expected to continue in 2017. A series of maps and accompanying chart summarize state legislation across six major “themes,” transparency, reimportation, pharmacy benefit managers, volume purchasing, research, and price regulation. These tools are the part of the NASHP Pharmacy Costs Workgroup, an ongoing project that looks beyond the strategies currently used in states to identify and develop new ideas, which address the growing problem of prescription drug costs.
NASHP’s Pharmacy Costs Work Group is comprised of state leaders from governors’ staff, state legislatures, Medicaid programs, public employees, attorney generals’ offices, state-based insurance exchanges, comptrollers’ offices, and corrections departments. The group aimed to find new approaches to limit pharmaceutical costs by examining the many levers state governments have as policymakers, regulators, and purchasers.
- Susan Barrett, J.D., Executive Director, Green Mountain Care Board
- Burl Beasley, D.Ph., MPH, MS Pharm Clinical Pharmacist, Oklahoma Health Care Authority
- Robert Crittenden, M.D., Senior Policy Advisor to Governor, Washington
- James DeBenedetti Director, Plan Management Division, Covered California
- Rebekah Gee, Secretary, Dept. of Health and Hospitals, State of Louisiana
- Rory Griffin, Deputy Director, Arkansas Dept. of Corrections
- Richard Gottfried, Chair, Committee on Health, New York Assembly
- Emily Hancock, RPH, Phar. D., MPA Clinical Pharmacist, Indiana Dept. of Social and Family Services
- Nathan Johnson, Chief Policy Officer, Washington State Health Care Authority
- Heather Korbulic, Executive Director, Silver State Health Insurance Exchange
- Kevin Lembo, Comptroller, State of Connecticut
- Janet Mills, J.D., Attorney General, State of Maine
- Rebecca Pasternik-Ikard, Chief Executive Officer, Oklahoma Health Care Authority
- Sara Sadownik, Deputy Chief of Staff, Massachusetts Health Policy Commission
- David Seltz, Executive Director, Massachusetts Health Care Commission
- Norman Thurston, Ph.D., Utah State Legislature
- Eileen Mallow, Deputy Director, WI Dept. of Employee Trust Funds
- Linda Wiant, Chief, Medical Assistance Plans, State of Georgia
- Josh Wojcik, Policy Director, Connecticut Office of the Comptroller
Interested in getting involved? Contact Corinne Alberts at email@example.com
NASHP’s Pharmacy Cost Workgroup is a diverse set of state leaders from across the nation, representing all perspectives in states – legislative and executive branch, Attorney’s General, Medicaid, Corrections and more, brought together to address growing concerns of rising drug prices. The aim of this group is to identify emerging strategies to address drug costs and to develop and test solutions. With support from the John and Laura Arnold Foundation and Kaiser Permante, the workgroup has developed background papers and engaged in deliberations about what states as purchasers, regulators and policymakers can do to address the trajectory of Rx prices. The result, “States and the Rising Costs of Pharmaceuticals: A Call to Action”, is a preliminary toolbox of options for state policymakers. NASHP is working with states to develop those options into practical, actionable solutions to address high cost prescription drug prices.
In this section you can access all the previous workgroup products including legislative tracking, background papers, policy proposals, and the model legislation.
- Supreme Court Decision Removes Barrier to Importing US Patented Drug Products at Lower Cost
This blog looks at how a recent Supreme Court decision on printer cartridges could help pave the way for wholesale drug importation. In Impression Products, Inc. v Lexmark International Inc., the Supreme Court ruled patent law cannot be used to prevent the resale of products back into the United States. The case is an important ruling in the context of the domestic policy debate concerning prescription drug pricing. Importation of prescription drugs as an antidote to the high prices in the U.S. is popular with the public and many policymakers.
- NASHP Releases Model Rx Transparency Legislation
NASHP, with guidance from our Pharmacy Costs Work Group, has developed a model transparency bill for states that wish to take a comprehensive approach to unlock the black box of pharmacy pricing and increase consumer awareness. This blog outlines the model transparency legislation and discusses what the bill does and does not do.
- State Wholesale Importation Explained
There is growing public pressure to find an effective way to address the rising prices of prescription drugs. Among the variety of approaches aimed at managing drug prices, importation from other countries is one that comes up repeatedly. The NASHP Pharmacy Costs Work Group believes there is a way for the federal government and states to get to ‘yes’ on a program of wholesale importation. The diverse group of state officials who comprise this Work Group have developed a wholesale drug importation program that would meet the major federal law criteria that the HHS Secretary must certify in order for a program to move forward.
- States and the Rising Cost of Pharmaceuticals: A Call to Action
This brief outlines 11 specific proposals ranging from regulatory interventions to more market-oriented approaches for states to consider when developing policies to help control rising pharmaceutical costs. The proposals focus on consumer protections, increasing oversight and price regulation and coordinating state purchasing power across public employees, Medicaid and Corrections
- State Legislative Action on Pharmaceutical Prices (Map)
As part of its work in pharmacy cost policy, NASHP tracks state legislation seeking to control the rising cost of prescription drugs. This series of maps summarize state legislation that has been introduced during the 2015-2016 legislative season. The six categories comprise the major “themes” seen in legislation.
- State Legislative Action on Pharmaceutical Prices (Chart)
As part of its work in pharmacy cost policy, NASHP tracks state legislation seeking to control the rising cost of prescription drugs. This chart summarize state legislation that has been introduced during the 2015-2016 legislative season. The six categories comprise the major “themes” seen in legislation
- States and Prescription Drugs: An Overview of State Programs to Rein in Costs
States are significant purchasers of health care for Medicaid, inmates in correctional facilities, and public employees. Despite considerable efforts to maintain affordability, drug pricing continues to vex state budgets. This paper provides an overview of current state programs to rein in drug costs.
- States and the Rising Cost of Pharmaceuticals: A Call to Action – Two Page Summary
This two page document gives an overview of the 11 policy proposals outlined in “States and the Rising Cost of Pharmaceuticals: A Call to Action.”
In this section please find registration and information for all upcoming webinars of the Pharmacy Cost Workgroup, as well as the recordings and slide decks of previous webinars.
States and the Rising Costs of Pharmaceuticals: A Call to Action, January 11th, 2017
NASHP, with guidance from our Pharmacy Costs Work Group, has developed model legislation for states that wish to pursue the policy options outlined in our paper States and the Rising Costs of Pharmaceuticals: A Call to Action. States interested in this model legislation will have access to a legislator’s guide and additional background materials as they become available. Please contact firstname.lastname@example.org if you wish to receive this state-only material.
Model Transparency Legislation
This model legislation is for states that wish to take a comprehensive approach to unlock the black box ofprescription drug pricing and increase consumer awareness.
Model Importation Legislation
The Work Group have developed a wholesale drug importation program that would ensure safety, cost savings, and meet the major federal law criteria that the HHS Secretary must certify in order for a program to move forward.